It's safe to say Illumina (NASDAQ:ILMN) has been one of the most impressive stories in health care over the past year. This up-and-coming game changer of a company has exploded onto the scene in the gene sequencing and diagnostics market, and investors who got in early have made out with huge profits. Illumina's stock has erupted for a nearly 200% gain over the past year. That's the kind of stellar growth that any smart investor can appreciate.
Yet Illumina might not be done. The company this week crushed analyst projections in its earnings report with a stellar fourth-quarter and full-year performance. Analysts have projected that the gene sequencing market that Illumina's looking to dominate could be worth up to $20 billion, and for this company and its investors, that's a huge prize just waiting to be capitalized on.
Can Illumina's stock keep up its stellar run? In the video below, Motley Fool contributor Dan Carroll takes you through Illumina's recent earnings results -- and where this company can go in a future that looks limitless.
Which under-the-radar stocks could transform your portfolio's potential this year?
As Illumina investors have made the most of, the best way for growth investors to play the health care space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.